Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Randomized Study of Nebulized vs Subcutaneous Morphine for Dyspnea in Terminal Cancer Patients (Summary Last Modified 06/95)

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

No phase specified

Supportive care

Closed

over 20

YALE-HIC-7849
NCI-V94-0591

Objectives

I.  Assess the efficacy of nebulized morphine on the dyspnea of terminal 
cancer patients.

II.  Compare the effects of subcutaneous vs. nebulized morphine on the dyspnea 
of terminal cancer patients.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:


Terminally ill cancer patients with dyspnea
  Age:  over 20

Concurrent narcotics for pain allowed

No known adverse effects from prior morphine

Expected Enrollment

32 patients will be randomized.  Probable duration of study is 2 years.

Outline

Randomized, crossover study.

Arm I:  Opioid Therapy.  Subcutaneous morphine.

Arm II:  Opioid Therapy.  Intranasal morphine.

Trial Contact Information

Trial Lead Organizations

Yale Cancer Center

Ann Berger, MD, MSN, Protocol chair(Contact information may not be current)
Ph: 860-785-6007; 866-925-3226

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.